ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia

Zhao, Zean; Liu, Jin; Kuang, Peihua; Luo, Jian; Surineni, Goverdhan; Cen, Xiaolin; Wu, Ting; Cao, Ying; Zhou, Pingzheng; Pang, Jianxin*; Zhang, Qun*; Chen, Jianjun*南方医科大学
European Journal of Medicinal Chemistry2022-2-5DOI: 10.1016/j.ejmech.2021.114092
9被引19阅读
引用收藏
分享

摘要

Verinurad (RDEA3170) is a selective URAT1 inhibitor under investigation for the treatment of gout and hyperuricemia. In an effort to further improve the pharmacodynamics/pharmacokinetics of verinurad and to increase the structural diversity, we designed novel verinurad analogs by introducing a linker (e.g. aminomethyl, amino or oxygen) between the naphthalene and the pyridine ring to increase the flexibility. These compounds were synthesized and tested for their in vitro URAT1-inhibitory activity. Most compounds exhibited potent inhibitory activities against URAT1 with IC50 values ranging from 0.24 mM to 16.35 mM. Among them, compound KPH2f exhibited the highest URAT1-inhibitory activity with IC50 of 0.24 mM, comparable to that of verinurad (IC50 1/4 0.17 mM). KPH2f also inhibited GLUT9 with an IC50 value of 9.37 +/- 7.10 mM, indicating the dual URAT1/GLUT9 targeting capability. In addition, KPH2f showed little effects on OAT1 and ABCG2, and thus was unlikely to cause OAT1/ABCG2-mediated drug-drug interactions and/or to neutralize the uricosuric effects of URAT1/GLUT9 inhibitors. Importantly, KPH2f (10 mg/kg) was equally effective in reducing serum uric acid levels and exhibited higher uricosuric effects in a mice hyperuricemia model, as compared to verinurad (10 mg/kg). Furthermore, KPH2f demonstrated favorable pharmacokinetic properties with an oral bioavailability of 30.13%, clearly better than that of verinurad (21.47%). Moreover, KPH2f presented benign safety profiles without causing hERG toxicity, cytotoxicity in vitro (lower than verinurad), and renal damage in vivo. Collectively, these results suggest that KPH2f represents a novel, safe and effective dual URAT1/GLUT9 inhibitor with improved druggabilities and is worthy of further investigation as an anti-hyperuricemic drug candidate.

学科与关键词

关键词
Verinuradanti-hyperuricemicDual inhibitorsURAT1GLUT9
相关
加载中…
  • CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia
    Zhao, Ze An; Jiang, Yu; Chen, Yan-yu; Wu, Ting; Lan, Qun-sheng; Li, Yong-mei; Li, Lu; Yang, Yang; Lin, Cui-ting; Cao, Ying; Zhou, Ping-zheng; Guo, Jia-yin*; Tian, Yuan-xin*; Pang, Jian-xin*Acta Pharmacologica Sinica, 2022, 43(1): 121-132.被引 15
  • Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors
    Zhang, Jian; Dong, Yue; Gao, Shenghua; Zhang, Xujie; Liao, Hui; Shi, Xiaoyu; Zhang, Zhijiao; Zhao, Tong; Liang, Ruipeng; Qi, Danhui; Wu, Ting*; Pang, Jianxin*; Liu, Xinyong*; Zhan, Peng*European Journal of Medicinal Chemistry, 2022, 244: 114816.被引 3
  • Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents
    Zhao, Zean; Liu, Jin; Yuan, Lin; Yang, Zichao; Kuang, Peihua; Liao, Hui; Luo, Jian; Feng, Huancun; Zheng, Fengxin; Chen, Yongjun; Wu, Ting; Guo, Jiayin; Cao, Ying; Yang, Yang; Lin, Cuiting; Zhang, Qun*; Chen, Jianjun*; Pang, Jianxin*European Journal of Medicinal Chemistry, 2022, 242: 114682.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2022-02-05
卷期
第 229 卷
页码
114092
DOI
10.1016/j.ejmech.2021.114092
语言
MULTI-LANGUAGE
期刊等级
1区
成果收录
SCIE
资助标注
National Foundation Science of China [81773794, 81974507]; Guangzhou Science and Technology Program Project [201903010087]; scientific research project of high-level talents in Southern Medical University of China [C1051008]; Thousand Youth Talents Program from the Organization Department of the CPC Central Committee, China [C1080092]; International Science and Technology Cooperation Projects of Guangdong Province [G819310411]

作者

  • Z

    Zhao, Zean (第一作者)

    new · southern med univ

  • L

    Liu, Jin

    new · southern med univ

查看全部 12 位作者收起作者
  • K

    Kuang, Peihua

    new · southern med univ

  • L

    Luo, Jian

    new · southern med univ

  • S

    Surineni, Goverdhan

    new · southern med univ

  • C

    Cen, Xiaolin

    southern med univ

  • W

    Wu, Ting

    new · southern med univ

  • C

    Cao, Ying

    new · southern med univ

  • Z

    Zhou, Pingzheng

    new · southern med univ

  • P

    Pang, Jianxin (通讯)

    southern med univ · new

  • Z

    Zhang, Qun (通讯)

    southern med univ

  • C

    Chen, Jianjun (通讯)

    southern med univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417